AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Provides research and development on medical sciences and pharmacy

The Pasteur Institute of Lille (French: Institut Pasteur de Lille, Pasteur-Lille, IPL) is a research centre and member of the Pasteur Institute network. It includes 14 research units and 1,150 employees including 626 researchers located in Lille, France. There are also 300 employees located outside the Pasteur site. Its revenues are above €70 million. Several neuroscience start-up companies have emerged from the Pasteur Institute of Lille.

Baiji Hongye (Nantong) Pharmaceutical Technology Co., Ltd., established on 2018-02-28, Business scope includes technology development in the field of medical science and technology,technology transfer,technical consulting,Technical Services;pharmaceutical production,operate;food,Medical device research and development.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Sichuan Kelun Botai Biomedical Co., Ltd., established on 2016-11-22, Business scope includes biopharmaceuticals,Chemical Raw Materials,Research and development of chemical preparations,production and sales;Import and export,Technology Import and Export;Technical extension services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. It offers DEL screening and library customization, chemical synthesis, and new drug research and development project transfer services. The company was founded by Jin Li on February 22, 2012 and is headquartered in Chengdu, China.

Nerviano Medical Sciences SRL provides pharmaceutical services. The company is headquartered in Nerviano, Italy.

Hangzhou Hezheng Pharmaceutical Co., Ltd., established on 2012-07-25, Business scope includes technology development,technical consulting,Technical Services,Achievement transfer:medical products,Pharmaceutical Intermediates,Biological product,Chemical Products(Removal of hazardous chemicals and precursor chemicals),Health products;wholesale,retail:Pharmaceutical Intermediates,Biochemical reagents(For scientific research and experiments,Removal of hazardous chemicals and precursor chemicals),Chemical Products(Removal of hazardous chemicals and precursor chemicals),Pre-packaged food(Does not contain refrigerated frozen food).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.